Patent Challenge Mechanism For FOBs Should Be Scrapped, FTC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Report views early patent resolution as unnecessary and potentially harmful to patent incentives and consumers.
You may also be interested in...
Follow-On Biologics “Integrally Related” To Patent Reform Bill, Sen. Hatch Says
Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.
Follow-On Biologics “Integrally Related” To Patent Reform Bill, Sen. Hatch Says
Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.
FTC’s Low Blow On FOBs
FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.